DISTEARYLDIMONIUM CHLORIDE
What is DISTEARYLDIMONIUM CHLORIDE (CAS 107-64-2) in cosmetics and what are its global regulatory limits?
DISTEARYLDIMONIUM CHLORIDE (CAS No. 107-64-2) is a verified cosmetic ingredient primarily functioning as Antistatic, Hair Conditioning in topical formulations. Regulated under KR MFDS (Unregulated) and EU 1223/2009 CosIng (Unregulated) statutory frameworks, it is typically formulated at 1.2–5% within an optimal stability window of pH 4–8.
7-Track Official Regulatory Label Names Matrix
Primary Statutory Gazette Only · Zero Machine Translation| Jurisdiction Track | Official Statutory Label Name | One-Click Copy |
|---|---|---|
| 1. Korea (MFDS Standard Name) | DISTEARYLDIMONIUM CHLORIDE (KR MFDS Registered) | |
| 2. Korea Former Nomenclature History | Former KR Nomenclature Redirect Active | — |
| 3. European Union (EU CosIng Glossary) | DISTEARYLDIMONIUM CHLORIDE | |
| 4. United States (US PCPC / MoCRA INCI) | DISTEARYLDIMONIUM CHLORIDE | |
| 5. US FDA OTC Monograph Active Name | — (Cosmetic Inactive / Non-OTC) | — |
| 6. China (NMPA IECIC Standard Name) | 二硬脂基二甲基氯化铵 | |
| 7. Japan (JCIA Standard / MHLW Quasi-Drug) | DISTEARYLDIMONIUM CHLORIDE (Standard INCI Reference) |
Layer 1 — Statutory Regulatory Limits Across 6 Regions
| Region | Status | Max Limit | Conditions & Statutory Source |
|---|---|---|---|
| Korea (MFDS) | Unregulated | GMP | Listed in official cosmetic inventory |
| Europe (EU) | Unregulated | GMP | Listed in official cosmetic inventory |
| United States (FDA) | Unregulated | GMP | Listed in official cosmetic inventory |
| China (NMPA) | Listed / Allowed | GMP | IECIC Entry #2241 |
| Japan (MHLW) | Unregulated | GMP | Listed in official cosmetic inventory |
| ASEAN (ACD) | Unregulated | GMP | Listed in official cosmetic inventory |
Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit
Layer 3 — Formulation Usage Guide (Quartiles n≥5) & Physicochemical Compatibility
| Formulation Group | Min – Q1 – Median – Q3 – Max (%) | Role & Mechanism | Source ID |
|---|---|---|---|
| Group B — O/W & W/O Emulsion / Lotion / Cream | 1.2% · 2.25% · 4% · 4.6875% · 5% | Emulsion cream & lotion structural / conditioning agent | Global Starter Formulation Library Statistical Distribution (n=14, EVONIK 14) |
Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery
Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.
pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior
Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.
Thermally stable up to 50°C during standard emulsification.
Cellular & Molecular Target Mechanism Flow
Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)
Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.
Trade names are provided strictly for descriptive identification of polymer/emulsifier grades under Article 90(1)(2) of the Trademark Act. All trademarks belong to their respective owners.
Academic & Toxicological Synthesis
Tier 1 SynthesisSynthesized strictly from peer-reviewed PubMed abstracts and official toxicological dossiers linked to this ingredient.
Linked Peer-Reviewed Literature (NIH PubMed) (1)
A novel water-in-oil emulsion with a lecithin-modified bentonite prevents skin damage from urban dust and cedar pollen. [PMID: 31995229 · 2020]
Particulate matter (PM), such as air pollutants and pollens, are known to cause skin ageing through skin inflammation. It is important to develop formulations which protect the skin from PM. We previously developed a conventional water-in-oil emulsion with a synthetic surfactant, distearyldimonium chloride, modified bentonite (C-W/O), which protects skin from allergens. In the present study, we developed a novel water-in-oil emulsion with a natural surfactant, lecithin, modified bentonite (N-W/O). The microarray analysis was performed using total RNA extracted from a reconstructed human epidermis (RHE) stimulated with urban aerosols or cedar pollen for 6 h in order to develop an epidermal inflammation model by PM for the evaluation of topical formulations. We then compared the efficacy of N-W/O and C-W/O to prevent epidermal degradation. Tissues and culture media were collected 24 h after the urban aerosol or cedar pollen stimulation for a histological assay, and the quantification of MMP1 and IL-8 secretion. The expression levels of proinflammatory cytokines and chemokines, such as IL1A and CXCL8, and matrix metalloproteinases, including MMP1, MMP3 and MMP9, were significantly up-regulated by the PM stimulation. As a result of ranking based on the pathway enrichment analysis, oxidative stress-related pathways, such as MAPK-mediated signalling, HIF-1 signalling, IL-1 signalling and ROS-induced cellular signalling, were ranked high in the urban dust- and cedar pollen-treated groups. A thickened stratum corneum, thinned vital layer and cleaved E-cadherin were observed by haematoxylin and eosin staining and immunohistochemical staining of E-cadherin in the PM treated groups. The secretion of MMP1 and IL-8 into the media was significantly increased by the PM stimulation. N-W/O prevented the degradation of epidermal integrity and secretion of inflammatory proteins more effectively than C-W/O. The present results showed that N-W/O made using natural surfactant is useful at protecting skin from PM, such as urban aerosols and cedar pollen. Les particules en suspensions (PM), telles que les polluants atmosphériques et les pollens, sont connues comme des causes de vieillissement de la peau par inflammation cutanée. Il est essentiel de mettre au point des formules qui protègent la peau contre ces particules. Par le passé, nous avons mis au point une émulsion eau-dans-huile classique composée d’un tensioactif synthétique, de distearyldimonium chloride et de bentonites modifiées (E/H-C), qui protège la peau contre les allergènes. Dans la présente étude, nous avons conçu une nouvelle émulsion eau-dans-huile composée d’un tensioactif naturel, de lécithine et de bentonites modifiées (N-E/H). MÉTHODES: L’analyse des microréseaux a été réalisée à l’aide de l’ARN total extrait d’un épiderme humain reconstitué (EHR) stimulé par les aérosols urbains ou le pollen de cèdre pendant 6 h afin de mettre au point un modèle d’inflammation de l’épiderme par les particules en suspensions en vue de l’évaluation des formulations topiques. Nous avons ensuite comparé l’efficacité de la N-E/H et de l’E/H-C dans le but d’éviter la dégradation de la peau. Les milieux de culture tissulaire ont été collectés 24 h après stimulation par l’aérosol urbain ou par du pollen de cèdre pour un dosage histologique et une quantification de MMP-1 et des sécrétions de l’IL-8. RÉSULTATS: Les niveaux d’expression des cytokines pro-inflammatoires et des chimiokines, à l’instar de l’IL1A et du CXCL8, ainsi que des métalloprotéinases matricielles, notamment les MMP1, les MMP3 et les MMP9, éta
Frequently Asked Questions (AEO Position 0)
- Q1. What are the official 7-track regulatory label names for DISTEARYLDIMONIUM CHLORIDE?
- Standard label names are US PCPC INCI: 'DISTEARYLDIMONIUM CHLORIDE', EU CosIng: 'DISTEARYLDIMONIUM CHLORIDE', KR MFDS: 'DISTEARYLDIMONIUM CHLORIDE (KR MFDS Registered)', CN NMPA IECIC: '二硬脂基二甲基氯化铵', and JP JCIA: 'DISTEARYLDIMONIUM CHLORIDE'.
- Q2. Is DISTEARYLDIMONIUM CHLORIDE restricted or permitted in EU, US, KR, CN, and JP cosmetics?
- Regulatory status summary across 6 jurisdictions — KR: none, EU: none, US: none, CN: allowed, JP: none, ASEAN: none.
- Q3. What is the typical formulation concentration and optimal pH window for DISTEARYLDIMONIUM CHLORIDE?
- In emulsion_cream systems, DISTEARYLDIMONIUM CHLORIDE is typically formulated between 1.2% and 5% (median 4%), with an optimal stability window of pH 4–8.
- Q4. What are the known formulation incompatibilities and synergy pairings for DISTEARYLDIMONIUM CHLORIDE?
- Recommended synergy pairings include GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL. Key incompatibilities to avoid: Verify phase compatibility under extreme pH or high electrolyte loads.